Tag: Pembrolizumab gastric cancer

Home / Pembrolizumab gastric cancer

Categories

Pembrolizumab is approved by the USFDA for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

On March 19, 2025, the Food and Drug Administration officially approved pembrolizumab (Keytruda, Merck) to be used along with trastuzumab and chemotherapy that includes fluoropyrimidine and platinum f...
pembrolizumab-gastric-cancer

Scan the code